CRISPR in 2026: From Gene Editing to Gene Therapy — What's Actually Working and What's Next
CRISPR has moved far beyond the lab. With the first approved gene therapies now treating patients, we examine what's working, what's failed, and the breakthroughs on the horizon.
infoz EditorialApril 3, 20267 min read
Share
Key Takeaways
•How CRISPR Works: A Quick Refresher
•Approved Therapies: What's Working Now
•What's in the Pipeline: The Next Wave
•The Delivery Problem: CRISPR's Biggest Challenge
•Ethical Debates: Where Are the Lines?
In December 2023, the FDA approved Casgevy — the world's first CRISPR-based gene therapy — to treat sickle cell disease. It was a watershed moment: a technology that was purely theoretical just a decade ago was now curing patients of a disease that had plagued humanity for millennia.
Two years later, the CRISPR revolution has accelerated far beyond that first approval. Here's where we stand in 2026.
How CRISPR Works: A Quick Refresher
CRISPR-Cas9 acts like a molecular GPS combined with scissors:
Guide RNA (gRNA) — A synthetic RNA sequence that matches the target DNA location
Cas9 protein — The "scissors" enzyme that cuts the DNA at the precise location
Cell repair — The cell's natural repair mechanisms fix the cut, either disabling a gene or inserting new DNA
Think of it this way: If your genome is a 3-billion-letter book, CRISPR lets you find one specific sentence and rewrite it — without affecting the rest of the book.
Generation
Technology
Capability
Accuracy
CRISPR 1.0
Cas9
Cut DNA (double-strand break)
~90% on-target
CRISPR 2.0
Base editing
Change single letters (no cut)
~95% on-target
CRISPR 3.0
Prime editing
Search-and-replace any sequence
~98% on-target
CRISPR 4.0
Epigenetic editing
Turn genes on/off without changing DNA
Under development
Approved Therapies: What's Working Now
Sickle Cell Disease & Beta-Thalassemia
Stay informed
Get the best articles delivered to your inbox. No spam, unsubscribe anytime.
Casgevy (exa-cel) by Vertex/CRISPR Therapeutics remains the flagship success:
How it works: Edits the BCL11A gene in patient's own stem cells, reactivating fetal hemoglobin production
Results: 97% of sickle cell patients are free from vaso-occlusive crises at 2-year follow-up
Cost: ~$2.2 million per treatment
Key limitation: Requires chemotherapy conditioning (myeloablative) before infusion
Real patient impact: Before treatment, patients averaged 8-10 pain crises per year requiring hospitalization. After: zero. Several patients have returned to full-time work and school for the first time in their lives.
Hereditary Angioedema
Intellia Therapeutics' NTLA-2002 received FDA approval in late 2025:
First in-vivo CRISPR therapy — injected directly into the bloodstream (no cell extraction needed)
Target: Edits the KLKB1 gene in liver cells
Results: 95% reduction in angioedema attacks after a single dose
Significance: Proves that CRISPR can be delivered systemically, not just to extracted cells
Transthyretin Amyloidosis (ATTR)
Intellia's NTLA-2001 is in late-stage trials:
Target: Knocks out the TTR gene in liver cells to stop misfolded protein production
Results: 93% reduction in serum TTR levels sustained at 2+ years
Potential: Could replace the $450,000/year drug patisiran for thousands of patients
What's in the Pipeline: The Next Wave
Cancer: CAR-T Gets a CRISPR Upgrade
Traditional CAR-T therapy engineers a patient's T-cells to attack cancer. CRISPR makes them dramatically better:
PD-1 knockout — Removes the "off switch" that tumors exploit to evade immune cells
Allogeneic (off-the-shelf) — CRISPR edits donor T-cells to prevent rejection, eliminating the need for patient-specific manufacturing
Multi-target — Simultaneously program T-cells to recognize multiple tumor antigens
Delivered directly to the retina via subretinal injection
Results: 5 of 14 patients showed clinically meaningful vision improvement
Next gen: Base editing approaches (no DNA cutting) are showing improved safety profiles
The Delivery Problem: CRISPR's Biggest Challenge
The technology works. Getting it to the right cells in the body remains the hardest problem:
Current Delivery Methods
Method
Pros
Cons
Best For
Ex vivo (edit cells outside body)
High efficiency, controllable
Requires cell extraction, expensive
Blood disorders, cancer
Lipid nanoparticles (LNPs)
Systemic delivery, well-understood
Mainly reaches liver
Liver diseases
AAV vectors
Can target specific tissues
Size limits, immune reactions
Eye, muscle, brain
Virus-like particles (VLPs)
Transient expression (safer)
Newer, less data
Emerging applications
The liver problem: LNPs naturally accumulate in the liver, making liver targets relatively easy. But delivering CRISPR to the brain, lungs, heart, or muscles remains extremely difficult.
2026 breakthroughs:
Engineered LNPs with tissue-specific targeting peptides (lung, muscle demonstrated in primates)
Exosome-based delivery showing promise for brain targets
Nebulized CRISPR for lung diseases entering clinical trials
Ethical Debates: Where Are the Lines?
Somatic vs. Germline Editing
Somatic editing (current therapies) only affects the treated individual. Changes don't pass to children. This is broadly accepted by the scientific community.
Germline editing (embryos, eggs, sperm) would create heritable changes — affecting all future generations. After He Jiankui's controversial 2018 experiment creating gene-edited babies, there is a global moratorium on clinical germline editing.
The consensus in 2026: Somatic gene therapy is a medical breakthrough to be celebrated and expanded. Germline editing requires far more research, safety data, and societal consensus before any clinical application.
Access and Equity
At $2.2 million per treatment, Casgevy is one of the most expensive therapies ever approved. The equity question is urgent:
Sickle cell disease disproportionately affects Black populations
Most patients are in Sub-Saharan Africa, where healthcare budgets are a fraction of US/EU levels
Current delivery models (hospital-based, chemotherapy conditioning) are impractical in low-resource settings
Promising developments:
In-vivo approaches (like Intellia's) could dramatically reduce costs by eliminating cell manufacturing
Outcome-based payment models: pay only if the therapy works
International initiatives to build CRISPR manufacturing capacity in Africa
Enhancement vs. Treatment
As the technology matures, the line between treating disease and enhancing normal traits blurs:
Reducing genetic disease risk? Broadly supported.
Enhancing muscle growth or cognitive function? Highly controversial.
Selecting for height, intelligence, or appearance? Widely opposed.
What's Next: 2026-2030 Predictions
10+ CRISPR therapies approved by 2028 (currently 2 approved, 50+ in trials)
In-vivo delivery beyond the liver — lung and muscle targets in clinical trials by 2027
Cost reduction — next-generation manufacturing could bring costs below $500K by 2028
Epigenetic editing enters clinical trials — turning genes on/off without permanent DNA changes
Combination therapies — CRISPR + mRNA + cell therapy for complex diseases like Type 1 diabetes
The Big Picture
CRISPR represents a fundamental shift in medicine — from managing symptoms to fixing root causes. For the first time in human history, we can rewrite the code of life with precision.
The technical challenges are real but solvable. The ethical questions require ongoing, inclusive dialogue. And the potential — to eliminate genetic disease, cure cancer, and extend healthy lifespan — is almost beyond comprehension.
We're not at the finish line. But we're no longer at the starting line either. The CRISPR era has begun.
The greatest medical revolution of our century isn't coming. It's already here.
CRISPR Gene Editing: What's Now Possible and What's Still Science Fiction
Gene editing has moved from laboratory curiosity to FDA-approved treatments. Here's what CRISPR can actually do today, what's coming next, and where the ethical lines are being drawn.